Active immunotherapy options for Alzheimer's disease.

Area of Science:

• Neuroscience
• Immunology
• Gerontology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia in older adults, characterized by amyloid-beta (Aβ) and tau protein accumulation.
• Current AD therapies offer symptomatic relief but do not address the underlying pathology.
• Research is focused on developing disease-modifying agents by investigating AD's molecular and cellular pathways.

Purpose of the Study:

• To review active immunotherapies for Alzheimer's disease currently under development.
• To discuss the benefits and challenges associated with active immunotherapy approaches for AD.
• To highlight the importance of early AD diagnosis and intervention in immunotherapy trials.

Main Methods:

• Review of preclinical and clinical data on active immunotherapies targeting Aβ.
• Examination of advancements in second-generation active immunotherapies.
• Assessment of the current status and potential of tau immunotherapy.

Main Results:

• Passive and active immunotherapies effectively reduce Aβ accumulation and downstream pathology in preclinical models.
• Second-generation active immunotherapies demonstrate improved antibody response and safety profiles.
• Preclinical data suggest tau immunotherapy is a viable area for clinical development.

Conclusions:

• Active immunotherapy, particularly targeting early Aβ accumulation, holds significant potential for modifying AD progression.
• Early diagnosis and intervention are crucial for maximizing the efficacy of active immunotherapy for AD.
• Continued research into both Aβ and tau immunotherapies is imperative for developing effective disease-modifying treatments for Alzheimer's disease.